Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2013 | Research

Pioglitazone counteracts the tumor necrosis factor-α inhibition of follicle-stimulating hormone-induced follicular development and estradiol production in an in vitro mouse preantral follicle culture system

Authors: Shuichiro Hara, Toshifumi Takahashi, Mitsuyoshi Amita, Koki Matsuo, Hideki Igarashi, Hirohisa Kurachi

Published in: Journal of Ovarian Research | Issue 1/2013

Abstract

Background

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age and is characterized by chronic anovulation. Insulin resistance may be a key component of the pathogenesis of this disorder. Pioglitazone is a thiazolidinedione derivative that acts by improving insulin resistance via the peroxisome proliferator-activated receptor-γ (PPAR-γ) pathway. Reportedly, pioglitazone improves the anovulation status in patients with PCOS. In the present study, we examined whether pioglitazone directly affects ovarian follicular development and steroidogenesis using in vitro mouse preantral follicle culture system.

Methods

An isolated individual in vitro mouse preantral follicle culture was used to test the effects of pioglitazone on the follicle development and steroidogenesis. Tumor necrosis factor-α (TNF-α), which plays a role in insulin resistance, has been reported to inhibit the follicle stimulating hormone (FSH)-induced follicular development and steroidogenesis in an in vitro mouse preantral follicle culture system. Therefore, we examined whether pioglitazone counteracts these effects by TNF-α. We assessed the follicle diameter and follicle survival and antral-like cavity formation rates, the 17β-estradiol (E2) levels in the culture medium, and the ovulation rate using the in vitro preantral follicle culture.

Results

Pioglitazone treatment counteracted the inhibition of TNF-α in FSH-induced follicle development in a dose-dependent manner. Pioglitazone, at a concentration of 5 μM, which was the minimum effective concentration, significantly counteracted the inhibition of TNF-α in FSH-induced follicle survival (29 versus 56%, P < 0.05), antral-like cavity formation (29 versus 48%, P < 0.05), E2 concentration in the culture medium (mean ± SEM = 21 ± 1 versus mean ± SEM = 27 ± 1 pg/mL, P < 0.05), and human chorionic gonadotropin-induced ovulation rate (9 versus 28%, P < 0.05).

Conclusions

Pioglitazone counteracted the inhibition by TNF-α on FSH-induced follicle development and steroidogenesis in the in vitro mouse preantral follicle culture. The results suggest that pioglitazone may directly affect the follicular development and steroidogenesis.

Available only for authorised users

Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF: A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000, 85: 2434–2438. 10.1210/jc.85.7.2434PubMed

American College of Obstetricians and Gynecologists: ACOG practice bulletin no. 108: polycystic ovary syndrome. Obstet Gynecol 2009, 114: 936–949. 10.1097/AOG.0b013e3181bd12cbCrossRef

Nestler JE: Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008, 358: 47–54. 10.1056/NEJMct0707092PubMedCrossRef

Amin M, Abdel-Kareem O, Takekida S, Moriyama T, Abd el-Aal G, Maruo T: Minireview: up-date management of non responder to clomiphene citrate in polycystic ovary syndrome. Kobe J Med Sci 2003, 49: 59–73.PubMed

Agarwal SK, Judd HL, Magoffin DA: A mechanism for the suppression of estrogen production in polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81: 3686–3691. 10.1210/jc.81.10.3686PubMed

Jakimiuk AJ, Weitsman SR, Brzechffa PR, Magoffin DA: Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol Hum Reprod 1998, 4: 1–8. 10.1093/molehr/4.1.1PubMedCrossRef

Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P: Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999, 48: 437–441. 10.1016/S0026-0495(99)90100-2PubMedCrossRef

Tarkun I, Cetinarslan B, Turemen E, Canturk Z, Biyikli M: Association between circulating tumor necrosis factor-alpha, interleukin-6, and insulin resistance in normal-weight women with polycystic ovary syndrome. Metab Syndr Relat Disord 2006, 4: 122–128. 10.1089/met.2006.4.122PubMedCrossRef

Morrison LJ, Marcinkiewicz JL: Tumor necrosis factor alpha enhances oocyte/follicle apoptosis in the neonatal rat ovary. Biol Reprod 2002, 66: 450–457. 10.1095/biolreprod66.2.450PubMedCrossRef

10.

Hussein MR: Apoptosis in the ovary: molecular mechanisms. Hum Reprod Update 2005, 11: 162–177.PubMedCrossRef

11.

Basini G, Mainardi GL, Bussolati S, Tamanini C: Steroidogenesis, proliferation and apoptosis in bovine granulosa cells: role of tumour necrosis factor-alpha and its possible signalling mechanisms. Reprod Fertil Dev 2002, 14: 141–150. 10.1071/RD01049PubMedCrossRef

12.

DeUgarte CM, Bartolucci AA, Azziz R: Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005, 83: 1454–1460. 10.1016/j.fertnstert.2004.11.070PubMedCrossRef

13.

Diamanti-Kandarakis E, Dunaif A: Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012, 33: 981–1030. 10.1210/er.2011-1034PubMedCrossRef

14.

Mathur R, Alexander CJ, Yano J, Trivax B, Azziz R: Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol 2008, 199: 596–609. 10.1016/j.ajog.2008.09.010PubMedCrossRef

15.

Kim CH, Jeon GH, Kim SR, Kim SH, Chae HD, Kang BM: Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertil Steril 2010, 94: 236–241. 10.1016/j.fertnstert.2009.02.029PubMedCrossRef

16.

Iuorno MJ, Nestler JE: Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001, 28: 153–164. 10.1016/S0889-8545(05)70191-1PubMedCrossRef

17.

Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH: Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012, 5: CD003053.PubMed

18.

Cariou B, Charbonnel B, Staels B: Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab 2012, 23: 205–215. 10.1016/j.tem.2012.03.001PubMedCrossRef

19.

Du Q, Yang S, Wang YJ, Wu B, Zhao YY, Fan B: Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials. Adv Ther 2012, 29: 763–774. 10.1007/s12325-012-0044-6PubMedCrossRef

20.

Koo YA, Shin SY, Yoon BK, Choi D: Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Gynecol Endocrinol 2007, 23: 461–467. 10.1080/09513590701492689PubMedCrossRef

21.

Ota H, Goto T, Yoshioka T, Ohyama N: Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril 2008, 90: 709–713. 10.1016/j.fertnstert.2007.01.117PubMedCrossRef

22.

Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Patel P, Holcomb K, Chang P, Poretsky L: Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 2005, 90: 6099–6105. 10.1210/jc.2005-0469PubMedCrossRef

23.

Hara S, Takahashi T, Amita M, Igarashi H, Tsutsumi S, Kurachi H: Bezafibrate restores the inhibition of FSH-induced follicular development and steroidogenesis by tumor necrosis factor-alpha through peroxisome proliferator-activated receptor-gamma pathway in an in vitro mouse preantral follicle culture. Biol Reprod 2011, 85: 895–906. 10.1095/biolreprod.111.090738PubMedCrossRef

24.

Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S: Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006, 166: 737–741. 10.1001/archinte.166.7.737PubMedCrossRef

25.

Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109: 2197–2202. 10.1161/01.CIR.0000126824.12785.B6PubMedCrossRef

26.

Lenie S, Smitz J: Functional AR signaling is evident in an in vitro mouse follicle culture bioassay that encompasses most stages of folliculogenesis. Biol Reprod 2009, 80: 685–695. 10.1095/biolreprod.107.067280PubMedCrossRef

27.

Adriaenssens T, Mazoyer C, Segers I, Wathlet S, Smitz J: Differences in collagen expression in cumulus cells after exposure to highly purified menotropin or recombinant follicle-stimulating hormone in a mouse follicle culture model. Biol Reprod 2009, 80: 1015–1025. 10.1095/biolreprod.107.067462PubMedCrossRef

28.

Lenie S, Cortvrindt R, Adriaenssens T, Smitz J: A reproducible two-step culture system for isolated primary mouse ovarian follicles as single functional units. Biol Reprod 2004, 71: 1730–1738. 10.1095/biolreprod.104.028415PubMedCrossRef

29.

Adriaens I, Cortvrindt R, Smitz J: Differential FSH exposure in preantral follicle culture has marked effects on folliculogenesis and oocyte developmental competence. Hum Reprod 2004, 19: 398–408. 10.1093/humrep/deh074PubMedCrossRef

30.

Cleveland JL, Ihle JN: Contenders in FasL/TNF death signaling. Cell 1995, 81: 479–482. 10.1016/0092-8674(95)90068-3PubMedCrossRef

31.

Amato G, Conte M, Mazziotti G, Lalli E, Vitolo G, Tucker AT, Bellastella A, Carella C, Izzo A: Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 2003, 101: 1177–1182. 10.1016/S0029-7844(03)00233-3PubMedCrossRef

32.

Choi YS, Yang HI, Cho S, Jung JA, Jeon YE, Kim HY, Seo SK, Lee BS: Serum asymmetric dimethylarginine, apelin, and tumor necrosis factor-alpha levels in non-obese women with polycystic ovary syndrome. Steroids 2012, 77: 1352–1358. 10.1016/j.steroids.2012.08.005PubMedCrossRef

33.

Nayudu PL, Osborn SM: Factors influencing the rate of preantral and antral growth of mouse ovarian follicles in vitro. J Reprod Fertil 1992, 95: 349–362. 10.1530/jrf.0.0950349PubMedCrossRef

34.

Hartshorne GM: In vitro culture of ovarian follicles. Rev Reprod 1997, 2: 94–104. 10.1530/ror.0.0020094PubMedCrossRef

35.

Cortvrindt RG, Smitz JE: Follicle culture in reproductive toxicology: a tool for in-vitro testing of ovarian function? Hum Reprod Update 2002, 8: 243–254. 10.1093/humupd/8.3.243PubMedCrossRef

36.

Gonzalez F: Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 2012, 77: 300–305. 10.1016/j.steroids.2011.12.003PubMedCentralPubMedCrossRef

37.

Montgomery Rice V, Limback SD, Roby KF, Terranova PF: Tumor necrosis factor alpha inhibition of follicle-stimulating hormone-induced granulosa cell estradiol secretion in the human does not involve reduction of cAMP secretion but inhibition at post-cAMP site(s). Endocrine 1999, 10: 19–23. 10.1385/ENDO:10:1:19PubMedCrossRef

38.

Abdo M, Hisheh S, Arfuso F, Dharmarajan A: The expression of tumor necrosis factor-alpha, its receptors and steroidogenic acute regulatory protein during corpus luteum regression. Reprod Biol Endocrinol 2008, 6: 50. 10.1186/1477-7827-6-50PubMedCentralPubMedCrossRef

39.

Ma Y, Ren S, Pandak WM, Li X, Ning Y, Lu C, Zhao F, Yin L: The effects of inflammatory cytokines on steroidogenic acute regulatory protein expression in macrophages. Inflamm Res 2007, 56: 495–501. 10.1007/s00011-007-6133-3PubMedCrossRef

40.

Cui Y, Miyoshi K, Claudio E, Siebenlist UK, Gonzalez FJ, Flaws J, Wagner KU, Hennighausen L: Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 2002, 277: 17830–17835. 10.1074/jbc.M200186200PubMedCrossRef

41.

Chen Q, Sun X, Chen J, Cheng L, Wang J, Wang Y, Sun Z: Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells. Reprod Biol Endocrinol 2009, 7: 147. 10.1186/1477-7827-7-147PubMedCentralPubMedCrossRef

42.

Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B, Wang LY, Yang SY, Zhang SH: Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clin Endocrinol (Oxf) 2011, 74: 332–339. 10.1111/j.1365-2265.2010.03917.xCrossRef

43.

Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, Chang RJ, Henry RR: Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 2009, 94: 469–476. 10.1210/jc.2008-1133PubMedCentralPubMedCrossRef

44.

Brettenthaler N, De Geyter C, Huber PR, Keller U: Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89: 3835–3840. 10.1210/jc.2003-031737PubMedCrossRef

45.

Kim CH, Ahn JW, You RM, Kim SH, Chae HD, Kang BM: Pioglitazone treatment decreases follicular fluid levels of tumor necrosis factor-alpha and interleukin-6 in patients with polycystic ovary syndrome. Clin Exp Reprod Med 2011, 38: 98–102. 10.5653/cerm.2011.38.2.98PubMedCentralPubMedCrossRef

46.

Ohama Y, Harada T, Iwabe T, Taniguchi F, Takenaka Y, Terakawa N: Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells. Fertil Steril 2008, 89: 311–317. 10.1016/j.fertnstert.2007.03.061PubMedCrossRef

47.

Sharma AM, Staels B: Review: peroxisome proliferator-activated receptor gamma and adipose tissue–understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007, 92: 386–395.PubMedCrossRef

Title: Pioglitazone counteracts the tumor necrosis factor-α inhibition of follicle-stimulating hormone-induced follicular development and estradiol production in an in vitro mouse preantral follicle culture system
Authors: Shuichiro Hara
Toshifumi Takahashi
Mitsuyoshi Amita
Koki Matsuo
Hideki Igarashi
Hirohisa Kurachi
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2013
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/1757-2215-6-69

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pioglitazone counteracts the tumor necrosis factor-α inhibition of follicle-stimulating hormone-induced follicular development and estradiol production in an in vitro mouse preantral follicle culture system

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Peritoneal full-conditioning reduces postoperative adhesions and pain: a randomised controlled trial in deep endometriosis surgery

Longitudinal health-related quality of life assessment: implications for prognosis in ovarian cancer

Insulin and insulin-like growth factor signaling increases proliferation and hyperplasia of the ovarian surface epithelium and decreases follicular integrity through upregulation of the PI3-kinase pathway

Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines

Pronuclear morphology evaluation in in vitro fertilization (IVF) / intracytoplasmic sperm injection (ICSI) cycles: a retrospective clinical review

RETRACTED ARTICLE: Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis